Thelansis

Primary Sclerosing Cholangitis (PSC) Market Outlook Thelansis’s “Primary Sclerosing Cholangitis (PSC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Sclerosing Cholangitis (PSC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

Primary Sclerosing Cholangitis (PSC) Market Outlook Thelansis’s “Primary Sclerosing Cholangitis (PSC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Sclerosing Cholangitis (PSC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Primary Sclerosing Cholangitis (PSC) Overview Primary Sclerosing Cholangitis (PSC) is a chronic liver condition characterized by the inflammation and progressive fibrosis of the bile ducts, leading to the formation of strictures (narrowing). This disease is strongly associated with Inflammatory Bowel Disease (IBD), with the majority of PSC patients having underlying IBD, most commonly ulcerative c...

 Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by inflammation and fibrosis of the bile ducts. It is closely linked to inflammatory bowel disease (IBD), and the extent of biliary system involvement can vary. Most PSC patients also have underlying IBD, such as ulcerative colitis or Crohn's disease. Ulcerative colitis is more common in PSC patients, accounting for 85% of cases, whereas Crohn's disease is less prevalent at 15%. Approximately 2.5-7.5% of all ulcerative colitis patients may develop PSC. In over 80% of PSC cases, strictures (narrowing of bile ducts) are present both within and outside the liver. However, around 10% only have intrahepatic strictures, and less than 5% have extrahepatic strictures exclusively. Most individuals with PSC are asymptomatic and are typically diagnosed through abnormal liver function tests in routine blood work. Despite advanced disease, many patients remain symptom-free for extended periods. The clinical cou...

  Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by bile duct inflammation and fibrosis and strongly associated with inflammatory bowel disease (IBD). There is variability in the extent of involvement of the biliary system. Most patients with primary sclerosing cholangitis have underlying inflammatory bowel diseases, such as ulcerative colitis or Crohn's disease. Patients with PSC are more likely to have ulcerative colitis than Crohn's disease (85% versus 15%), with approximately 2.5-7.5% of all ulcerative colitis patients having primary sclerosing cholangitis. In more than 80% of patients, the strictures are located in both the intrahepatic and extrahepatic ducts. However, about 10% of these patients have intrahepatic strictures only, while less than 5% will have only extrahepatic strictures. The majority of people with PSC have no symptoms. These patients are typically diagnosed when abnormal biochemical tests of liver function are detected du...